Altimmune
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.About ALT
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.
ALT Key Statistics
Stock Snapshot
With a market cap of 362.3M, Altimmune(ALT) trades at $4.10. The stock has a price-to-earnings ratio of -3.85.
During the trading session on 2025-11-08, Altimmune(ALT) shares reached a daily high of $4.16 and a low of $3.76. At a current price of $4.10, the stock is +9.0% higher than the low and still -1.3% under the high.
Trading volume for Altimmune(ALT) stock has reached 4.26M, versus its average volume of 3M.
The stock's 52-week range extends from a low of $2.90 to a high of $11.16.
The stock's 52-week range extends from a low of $2.90 to a high of $11.16.
ALT News
Altimmune (ALT) announced results from an artificial intelligence-based analysis of biopsies from the IMPACT Phase 2b trial of pemvidutide in patients with meta...
Altimmune ( (ALT) ) has released its Q3 earnings. Here is a breakdown of the information Altimmune presented to its investors. Meet Your ETF AI Analyst Discov...
Altimmune ((ALT)) has held its Q3 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can...
Analyst ratings
78%
of 9 ratingsMore ALT News
William Blair analyst Andy Hsieh has reiterated their neutral stance on ALT stock, giving a Hold rating yesterday. Meet Your ETF AI Analyst Discover how TipRank...
Earnings Call Insights Altimmune outlines flexible Phase III design and regulatory milestones while strengthening leadership Nov. 06, 2025 2:27 PM ET Altimmune,...
Reports Q3 revenue $5,000, consensus $560,000. “We have made a number of important advancements in the second half of 2025 and are approaching a major inflectio...
Altimmune (ALT) announced the completion of patient enrollment in RECLAIM, a Phase 2 clinical trial evaluating pemvidutide in adults with alcohol use disorder,...